Target Price | $45.07 |
Price | $44.71 |
Potential | 0.81% |
Number of Estimates | 14 |
14 Analysts have issued a price target Exelon 2026 . The average Exelon target price is $45.07. This is 0.81% higher than the current stock price. The highest price target is $48.00 7.36% , the lowest is $41.00 8.30% . | |
A rating was issued by 20 analysts: 8 Analysts recommend Exelon to buy, 9 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Exelon stock has an average upside potential 2026 of 0.81% . Most analysts recommend the Exelon stock at Hold. |
11 Analysts have issued a sales forecast Exelon 2025 . The average Exelon sales estimate is $22.9b . This is 0.38% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $24.1b 4.84% , the lowest is $20.6b 10.58% .
This results in the following potential growth metrics:
2024 | $23.0b | 5.99% |
---|---|---|
2025 | $22.9b | 0.37% |
2026 | $23.7b | 3.28% |
2027 | $24.1b | 1.65% |
2028 | $24.8b | 3.05% |
2029 | $25.3b | 1.91% |
10 Analysts have issued an Exelon EBITDA forecast 2025. The average Exelon EBITDA estimate is $8.8b . This is 11.67% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $9.3b 17.08% , the lowest is $8.1b 1.91% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $7.9b | 5.14% |
---|---|---|
2025 | $8.8b | 11.70% |
2026 | $9.4b | 7.02% |
2027 | $10.1b | 6.48% |
2028 | $11.2b | 11.23% |
2029 | $12.1b | 7.70% |
2024 | 34.31% | 0.80% |
---|---|---|
2025 | 38.47% | 12.11% |
2026 | 39.87% | 3.64% |
2027 | 41.76% | 4.74% |
2028 | 45.08% | 7.95% |
2029 | 47.64% | 5.68% |
6 Exelon Analysts have issued a net profit forecast 2025. The average Exelon net profit estimate is $2.7b . This is 9.25% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 10.61% , the lowest is $2.7b 7.74% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.5b | 4.70% |
---|---|---|
2025 | $2.7b | 9.25% |
2026 | $2.8b | 5.03% |
2027 | $3.0b | 6.77% |
2028 | $3.2b | 5.03% |
2029 | $3.3b | 5.32% |
2024 | 10.69% | 1.21% |
---|---|---|
2025 | 11.72% | 9.61% |
2026 | 11.92% | 1.71% |
2027 | 12.52% | 5.03% |
2028 | 12.76% | 1.92% |
2029 | 13.19% | 3.37% |
6 Analysts have issued a Exelon forecast for earnings per share. The average Exelon EPS is $2.68 . This is 9.39% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.71 10.61% , the lowest is $2.64 7.76% .
This results in the following potential growth metrics and future valuations:
2024 | $2.45 | 4.70% |
---|---|---|
2025 | $2.68 | 9.39% |
2026 | $2.81 | 4.85% |
2027 | $3.00 | 6.76% |
2028 | $3.15 | 5.00% |
2029 | $3.32 | 5.40% |
Current | 18.23 | 16.04% |
---|---|---|
2025 | 16.70 | 8.39% |
2026 | 15.90 | 4.79% |
2027 | 14.90 | 6.29% |
2028 | 14.18 | 4.83% |
2029 | 13.47 | 5.01% |
Based on analysts' sales estimates for 2025, the Exelon stock is valued at an EV/Sales of 3.98 and an P/S ratio of 1.97 .
This results in the following potential growth metrics and future valuations:
Current | 3.97 | 8.17% |
---|---|---|
2025 | 3.98 | 0.26% |
2026 | 3.85 | 3.17% |
2027 | 3.79 | 1.62% |
2028 | 3.68 | 2.96% |
2029 | 3.61 | 1.88% |
Current | 1.96 | 16.08% |
---|---|---|
2025 | 1.97 | 0.38% |
2026 | 1.91 | 3.17% |
2027 | 1.87 | 1.63% |
2028 | 1.82 | 2.96% |
2029 | 1.78 | 1.88% |
Analyst | Rating | Action | Date |
---|---|---|---|
UBS |
Neutral
➜
Neutral
|
Unchanged | Mar 21 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Mar 20 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 25 2025 |
Scotiabank |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 13 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Jan 22 2025 |
Evercore ISI Group |
In-Line
➜
Outperform
|
Upgrade | Jan 21 2025 |
Scotiabank |
Sector Perform
➜
Sector Perform
|
Unchanged | Dec 12 2024 |
Analyst Rating | Date |
---|---|
Unchanged
UBS:
Neutral
➜
Neutral
|
Mar 21 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Mar 20 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 25 2025 |
Unchanged
Scotiabank:
Sector Perform
➜
Sector Perform
|
Feb 13 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jan 22 2025 |
Upgrade
Evercore ISI Group:
In-Line
➜
Outperform
|
Jan 21 2025 |
Unchanged
Scotiabank:
Sector Perform
➜
Sector Perform
|
Dec 12 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.